An evaluation of roflumilast and PDE4 inhibitors with a focus on the treatment of asthma

Long-term Triple Therapy De-escalation to Indacaterol/Glycopyrronium in COPD Patients (SUNSET): a Randomized, Double-Blind, Triple-Dummy Clinical Trial

(2018) Kenneth R Chapman et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Determinants of Response to Roflumilast in Severe COPD: Pooled Analysis of Two Randomized Trials

(2018) Fernando J. Martinez et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Cigarette smoke up-regulates PDE3 and PDE4 to decrease cAMP in airway cells

(2018) Haoxiao Zuo et al.   BRITISH JOURNAL OF PHARMACOLOGY

Pharmacokinetic and Pharmacodynamic Modelling to Characterize the Tolerability of Alternative Up-Titration Regimens of Roflumilast in Patients with Chronic Obstructive Pulmonary Disease

(2018) Axel Facius et al.   CLINICAL PHARMACOKINETICS

Asthma-COPD Overlap Phenotypes and Smoking :Comparative features of asthma in smoking or non-smoking patients with an incomplete reversibility of airway obstruction

(2018) Louis-Philippe Boulet et al.   COPD-Journal of Chronic Obstructive Pulmonary Disease

A randomised clinical trial of feedback on inhaler adherence and technique in patients with severe uncontrolled asthma

(2018) Imran Sulaiman et al.   EUROPEAN RESPIRATORY JOURNAL

Asthma

(2018) Alberto Papi et al.   LANCET

Inhaled Combined Budesonide–Formoterol as Needed in Mild Asthma

(2018) Paul M. O’Byrne et al.   NEW ENGLAND JOURNAL OF MEDICINE

As-Needed Budesonide–Formoterol versus Maintenance Budesonide in Mild Asthma

(2018) Eric D. Bateman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma

(2018) Mario Castro et al.   NEW ENGLAND JOURNAL OF MEDICINE

Once-Daily Single-Inhaler Triple versus Dual Therapy in Patients with COPD

(2018) David A. Lipson et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy and safety of phosphodiesterase 4 inhibitors in patients with asthma: A systematic review and meta-analysis

(2018) Jian Luo et al.   RESPIROLOGY

Evolving Concepts in Asthma

(2018) Paul O'Byrne   SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE

Phenotyping COPD exacerbations using imaging and blood-based biomarkers

(2018) Nawaf M Alotaibi et al.   International Journal of Chronic Obstructive Pulmonary Disease

Prevention of COPD exacerbations: a European Respiratory Society/American Thoracic Society guideline

(2017) Jadwiga A. Wedzicha et al.   EUROPEAN RESPIRATORY JOURNAL

A simple algorithm for the identification of clinical COPD phenotypes

(2017) Pierre-Régis Burgel et al.   EUROPEAN RESPIRATORY JOURNAL

Tezepelumab in Adults with Uncontrolled Asthma

(2017) Jonathan Corren et al.   NEW ENGLAND JOURNAL OF MEDICINE

The impact of inappropriate use of short acting beta agonists in asthma

(2017) J. Mark FitzGerald et al.   RESPIRATORY MEDICINE

Chronic obstructive pulmonary disease phenotypes, biomarkers, and prognostic indicators

(2016) Christopher E. Brightling   ALLERGY AND ASTHMA PROCEEDINGS

The dual phosphodiesterase 3 and 4 inhibitor RPL554 stimulates CFTR and ciliary beating in primary cultures of bronchial epithelia

(2016) Mark J. Turner et al.   AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY

Effect of Roflumilast and Inhaled Corticosteroid/Long-Acting β2-Agonist on Chronic Obstructive Pulmonary Disease Exacerbations (RE2SPOND). A Randomized Clinical Trial

(2016) Fernando J. Martinez et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Novel relaxant effects of RPL554 on guinea pig tracheal smooth muscle contractility

(2016) R Venkatasamy et al.   BRITISH JOURNAL OF PHARMACOLOGY

Roflumilast combined with montelukast versus montelukast alone as add-on treatment in patients with moderate-to-severe asthma

(2016) Eric D. Bateman et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial

(2016) Sally Wenzel et al.   LANCET

Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial

(2016) J Mark FitzGerald et al.   LANCET

A novel inhaled phosphodiesterase 4 inhibitor (CHF6001) reduces the allergen challenge response in asthmatic patients

(2016) D. Singh et al.   PULMONARY PHARMACOLOGY & THERAPEUTICS

Early efficacy of budesonide/formoterol in patients with moderate-to-very-severe COPD

(2016) Peter MA Calverley et al.   International Journal of Chronic Obstructive Pulmonary Disease

Efficacy and safety of a CXCR2 antagonist, AZD5069, in patients with uncontrolled persistent asthma: a randomised, double-blind, placebo-controlled trial

(2016) Paul M O'Byrne et al.   Lancet Respiratory Medicine

Regulation of human skin mast cell histamine release by PDE inhibitors

(2015) N. Eskandari et al.   ALLERGOLOGIA ET IMMUNOPATHOLOGIA

Emerging molecular phenotypes of asthma

(2015) Anuradha Ray et al.   AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY

Asthma phenotypes and the use of biologic medications in asthma and allergic disease: The next steps toward personalized care

(2015) Merritt L. Fajt et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Effect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multicentre randomised controlled trial

(2015) Fernando J Martinez et al.   LANCET

The Asthma–COPD Overlap Syndrome

(2015) Dirkje S. Postma et al.   NEW ENGLAND JOURNAL OF MEDICINE

Roflumilast for asthma: Efficacy findings in mechanism of action studies

(2015) P. Bardin et al.   PULMONARY PHARMACOLOGY & THERAPEUTICS

Roflumilast for asthma: Efficacy findings in placebo-controlled studies

(2015) E.O. Meltzer et al.   PULMONARY PHARMACOLOGY & THERAPEUTICS

Roflumilast for asthma: Safety findings from a pooled analysis of ten clinical studies

(2015) P. Chervinsky et al.   PULMONARY PHARMACOLOGY & THERAPEUTICS

Pharmacological characterization of the interaction between the dual phosphodiesterase (PDE) 3/4 inhibitor RPL554 and glycopyrronium on human isolated bronchi and small airways

(2015) Luigino Calzetta et al.   PULMONARY PHARMACOLOGY & THERAPEUTICS

Roflumilast added to triple therapy in patients with severe COPD: A real life study

(2015) Mariana Muñoz-Esquerre et al.   PULMONARY PHARMACOLOGY & THERAPEUTICS

Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials

(2015) Mario Castro et al.   Lancet Respiratory Medicine

Asthma and COPD Overlap Syndrome (ACOS): A Systematic Review and Meta Analysis

(2015) A. Alshabanat et al.   PLoS One

Sputum gene expression signature of 6 biomarkers discriminates asthma inflammatory phenotypes

(2014) Katherine J. Baines et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Effects of an Anti-TSLP Antibody on Allergen-Induced Asthmatic Responses

(2014) Gail M. Gauvreau et al.   NEW ENGLAND JOURNAL OF MEDICINE

Mepolizumab Treatment in Patients with Severe Eosinophilic Asthma

(2014) Hector G. Ortega et al.   NEW ENGLAND JOURNAL OF MEDICINE

The effect of the novel phosphodiesterase-4 inhibitor MEM 1414 on the allergen induced responses in mild asthma

(2014) Brian R Leaker et al.   BMC Pulmonary Medicine

Benralizumab, an anti-interleukin 5 receptor α monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study

(2014) Mario Castro et al.   Lancet Respiratory Medicine

Randomized, Double-Blind, Placebo-controlled Study of Brodalumab, a Human Anti–IL-17 Receptor Monoclonal Antibody, in Moderate to Severe Asthma

(2013) William W. Busse et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Mechanisms of Airway Remodeling

(2013) Nobuaki Hirota et al.   CHEST

Efficacy and safety of roflumilast in patients with stable chronic obstructive pulmonary disease: A meta-analysis

(2013) Jun-Hong Yan et al.   PULMONARY PHARMACOLOGY & THERAPEUTICS

Inhibition of PDE4B suppresses inflammation by increasing expression of the deubiquitinase CYLD

(2013) Kensei Komatsu et al.   Nature Communications

Efficacy and safety of RPL554, a dual PDE3 and PDE4 inhibitor, in healthy volunteers and in patients with asthma or chronic obstructive pulmonary disease: findings from four clinical trials

(2013) Lui G Franciosi et al.   Lancet Respiratory Medicine

Safety and efficacy of a CXCR2 antagonist in patients with severe asthma and sputum neutrophils: a randomized, placebo-controlled clinical trial

(2012) P. Nair et al.   CLINICAL AND EXPERIMENTAL ALLERGY

Severe asthma: future treatments

(2012) P. M. O'Byrne et al.   CLINICAL AND EXPERIMENTAL ALLERGY

Roflumilast inhibits the release of chemokines and TNF-α from human lung macrophages stimulated with lipopolysaccharide

(2011) A Buenestado et al.   BRITISH JOURNAL OF PHARMACOLOGY

Physiological effects of roflumilast at rest and during exercise in COPD

(2011) Denis E. O’Donnell et al.   EUROPEAN RESPIRATORY JOURNAL

Roflumilast with long-acting  2-agonists for COPD: influence of exacerbation history

(2011) E. D. Bateman et al.   EUROPEAN RESPIRATORY JOURNAL

Asthma endotypes: A new approach to classification of disease entities within the asthma syndrome

(2011) Jan Lötvall et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Patterns of Inflammatory Responses in Large and Small Airways in Smokers with and without Chronic Obstructive Pulmonary Disease

(2011) Sergejs Isajevs et al.   RESPIRATION

The differential impact of PDE4 subtypes in human lung fibroblasts on cytokine-induced proliferation and myofibroblast conversion

(2010) Jens Selige et al.   JOURNAL OF CELLULAR PHYSIOLOGY

PDE4 inhibition drives resolution of neutrophilic inflammation by inducing apoptosis in a PKA-PI3K/Akt-dependent and NF-κB-independent manner

(2010) Lirlândia P. Sousa et al.   JOURNAL OF LEUKOCYTE BIOLOGY

Susceptibility to Exacerbation in Chronic Obstructive Pulmonary Disease

(2010) John R. Hurst et al.   NEW ENGLAND JOURNAL OF MEDICINE

Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials

(2009) Leonardo M Fabbri et al.   LANCET

Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials

(2009) Peter MA Calverley et al.   LANCET

Mepolizumab for Prednisone-Dependent Asthma with Sputum Eosinophilia

(2009) Parameswaran Nair et al.   NEW ENGLAND JOURNAL OF MEDICINE

Randomized, placebo-controlled study of a selective PDE4 inhibitor in the treatment of asthma

(2009) Susan Lu et al.   RESPIRATORY MEDICINE

Role of IL-10 in the Resolution of Airway Inflammation

(2008) Yoshiko Ogawa et al.   CURRENT MOLECULAR MEDICINE

Roflumilast attenuates pulmonary inflammation upon segmental endotoxin challenge in healthy subjects: A randomized placebo-controlled trial

(2008) Jens M. Hohlfeld et al.   PULMONARY PHARMACOLOGY & THERAPEUTICS

A Major Functional Role for Phosphodiesterase 4D5 in Human Airway Smooth Muscle Cells

(2007) Charlotte K. Billington et al.   AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY